HomeCompareCLVS vs EPRT

CLVS vs EPRT: Dividend Comparison 2026

CLVS yields 2463.05% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CLVS wins by $70041530665.26M in total portfolio value
10 years
CLVS
CLVS
● Live price
2463.05%
Share price
$0.08
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$70041530665.32M
Annual income
$64,861,296,013,860,630.00
Full CLVS calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — CLVS vs EPRT

📍 CLVS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCLVSEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CLVS + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CLVS pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CLVS
Annual income on $10K today (after 15% tax)
$209,359.61/yr
After 10yr DRIP, annual income (after tax)
$55,132,101,611,781,540.00/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, CLVS beats the other by $55,132,101,611,770,620.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CLVS + EPRT for your $10,000?

CLVS: 50%EPRT: 50%
100% EPRT50/50100% CLVS
Portfolio after 10yr
$35020765332.69M
Annual income
$32,430,648,006,936,736.00/yr
Blended yield
92.60%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

CLVS
Analyst Ratings
11
Buy
10
Hold
4
Sell
Consensus: Buy
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CLVS buys
0
EPRT buys
0
No recent congressional trades found for CLVS or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCLVSEPRT
Forward yield2463.05%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$70041530665.32M$63.4K
Annual income after 10y$64,861,296,013,860,630.00$12,840.73
Total dividends collected$69679216448.03M$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: CLVS vs EPRT ($10,000, DRIP)

YearCLVS PortfolioCLVS Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$257,005$246,305.42$11,205$505.18+$245.8KCLVS
2$6,191,054$5,916,058.62$12,672$682.46+$6.18MCLVS
3$139,814,248$133,189,820.21$14,490$930.48+$139.80MCLVS
4$2,960,686,816$2,811,085,570.49$16,786$1,282.69+$2960.67MCLVS
5$58,800,787,025$55,632,852,131.69$19,753$1,791.56+$58800.77MCLVS
6$1,095,531,336,986$1,032,614,494,869.48$23,677$2,541.64+$1095531.31MCLVS
7$19,152,484,228,807$17,980,265,698,231.36$29,008$3,672.99+$19152484.20MCLVS
8$314,266,670,684,876$293,773,512,560,052.56$36,463$5,425.08+$314266670.65MCLVS
9$4,841,340,795,759,426$4,505,075,458,126,609.00$47,238$8,221.57+$4841340795.71MCLVS
10$70,041,530,665,323,210$64,861,296,013,860,630.00$63,385$12,840.73+$70041530665.26MCLVS

CLVS vs EPRT: Complete Analysis 2026

CLVSStock

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is also developing lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3);and FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. In addition, the company sells its Rubraca through a limited number of specialty distributor and specialty pharmacy providers, who subsequently sells Rubraca to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, a clinical collaboration with Bristol Myers Squibb Company; and a partnership with Foundation Medicine, Inc. Clovis Oncology, Inc. was incorporated in 2009 and is headquartered in Boulder, Colorado. On December 11, 2022, Clovis Oncology, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Full CLVS Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this CLVS vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CLVS vs SCHDCLVS vs JEPICLVS vs OCLVS vs KOCLVS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.